Shots: The application is based on two studies i.e P-III EINSTEIN-Jr & UNIVERSE. The P-III EINSTEIN-Jr study evaluates Xarelto in 500 children in a ratio (2:1) aged birth to 17yrs. […]readmore
Tags : rivaroxaban
Shots: Bayer has submitted MAA to EMA based on P-III EINSTEIN-Jr. study evaluating Rivaroxaban vs SOC in 500 children in a ratio (2:1) aged from birth to 17yrs. with documented […]readmore
Shots: The approval is based on P-III MAGELLAN study assessing Xarelto in preventing VTE in patients with acute medical illnesses, at risk for thromboembolic complications who are not at high […]readmore
Shots: The ESC has published new clinical practice guidelines to manage diabetes and CCS, replacing 2013 recommendations for the management of stable coronary artery disease and recommends Bayer’s Xarelto (2.5mg, […]readmore
Shots: The P-III EINSTEIN-Jr. study involves assessing of Xarelto (20mg) vs SOC (heparins as monothx. or in combination with Vit.K antagonist like warfarin) in 500 children in ratio (2:1) with […]readmore